A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage-Reference-Cited by-同舟云学术

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of High-Dose Rebamipide Treatment for Low-Dose Aspirin-Induced Moderate-to-Severe Small Intestinal Damage

Published:2015-04-15 Issue:4 Volume:10 Page:e0122330
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Watanabe Toshio,Takeuchi Toshihisa,Handa Osamu,Sakata Yasuhisa,Tanigawa Tetsuya,Shiba Masatsugu,Naito Yuji,Higuchi Kazuhide,Fujimoto Kazuma,Yoshikawa Toshikazu,Arakawa Tetsuo

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference30 articles.

1. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial;H Ogawa;JAMA,2008

2. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women;PM Ridker;N Engl J Med,2005

3. Aspirin for primary prevention of cardiovascular events: meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status;M Xie;PLoS One,2014

4. Small bowel injury by low-dose enteric-coated aspirin and treatment with misoprostol: a pilot study;T Watanabe;Clin Gastroenterol Hepatol,2008

5. Low-dose aspirin affects the small bowel mucosa: results of a pilot study with a multidimensional assessment;E Smecuol;Clin Gastroenterol Hepatol,2009

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drugs Effective for Nonsteroidal Anti-inflammatory Drugs or Aspirin-induced Small Bowel Injuries;Journal of Clinical Gastroenterology;2024-07-16

2. Gastroprotective therapy in patients with atrial fibrillation receiving anticoagulant therapy: A review;Consilium Medicum;2023-07-30

3. Protective Effect of Irsogladine against Aspirin-Induced Mucosal Injury in Human Induced Pluripotent Stem Cell-Derived Small Intestine;Medicina;2022-12-31

4. Gastroprotectant Rebamipide: review of action mechanisms and clinical applications;Glavvrač (Chief Medical Officer);2022-03-20

5. Risk of Post-Myocardial Infarction Pneumonia with Proton Pump Inhibitors, H2 Receptor Antagonists and Mucoprotective Agents: A Retrospective Nationwide Cohort Study;Journal of Personalized Medicine;2022-01-09